Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host Disease

home / insights / focus-on-pathways-targeting-the-csf-1r-pathway-in-graft-vs-host-disease

Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.

Hannah Choe, MD, an expert on GVHD

EP. 1: Graft-Versus-Host Disease: Pathogenesis, Clinical Challenges, and Unmet Treatment Needs

Hannah Choe, MD
July 8th 2024

In this video, Dr. Hannah Choe provides an overview of the background of graft-versus-host disease (GVHD), discusses currently approved treatments and their limitations, and the significant unmet treatment needs in GVHD.

Hannah Choe, MD, an expert on GVHD

EP. 2: The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway

Hannah Choe, MD
July 8th 2024

Dr. Choe discusses the potential role of the CSF-1R signaling pathway in the pathogenesis of numerous diseases, including GVHD. A video segment explores how dysregulation of this pathway can contribute to the development and progression of GVHD, providing the rationale for targeting CSF-1R as a potential therapeutic strategy.

Hannah Choe, MD, an expert on GVHD

EP. 3: AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD

Hannah Choe, MD
July 17th 2024

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

Hannah Choe, MD, an expert on GVHD

EP. 4: Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD

Hannah Choe, MD
July 17th 2024

Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.